{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:23:49Z","timestamp":1792783429357,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000646","name":"Japan Society for the Promotion of Science London","doi-asserted-by":"publisher","award":["24K11563"],"award-info":[{"award-number":["24K11563"]}],"id":[{"id":"10.13039\/501100000646","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Kumamoto University","id":[{"id":"https:\/\/ror.org\/02cgss904","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Primary and secondary central nervous system lymphomas (PCNSL and SCNSL, respectively) are aggressive non-Hodgkin lymphomas with high relapse risk. Methotrexate rarely achieves durable remission, necessitating combination therapy or consolidation. Although high-dose busulfan and thiotepa (BuTT) conditioning followed by autologous stem cell transplantation (ASCT) is a promising consolidation strategy, the optimal timing and real-world outcomes of ASCT remain unclear. We retrospectively analyzed 12 patients (eight with PCNSL and four with SCNSL) treated with BuTT\/ASCT at a single center between 2019 and 2024. Nine patients underwent upfront ASCT shortly after achieving complete remission with rituximab, methotrexate, procarbazine, and vincristine and remained in remission at a median follow-up of 681\u00a0days (range, 147\u20131322\u00a0days). Three patients (two with PCNSL and one with SCNSL) who underwent salvage ASCT following multiple prior therapies experienced early relapse (51\u2013125\u00a0days post-ASCT) and died of their disease. BuTT\/ASCT is highly effective when administered promptly after remission, whereas salvage ASCT after multiple therapies is associated with poor outcomes. Timely clinical decision-making and upfront consolidation may be key to optimizing the therapeutic benefits of ASCT in CNSL, although further validation is warranted.<\/jats:p>","DOI":"10.1007\/s12185-026-04267-2","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:33:01Z","timestamp":1787167981000},"page":"495-501","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Timing of autologous stem cell transplantation and induction response in central nervous system lymphoma"],"prefix":"10.1007","volume":"124","author":[{"given":"Yusuke","family":"Higuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8131-3401","authenticated-orcid":false,"given":"Hiro","family":"Tatetsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taichi","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Shichijo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asami","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shikiko","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Takezaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichiro","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Shinojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kisato","family":"Nosaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akitake","family":"Mukasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-ichirou","family":"Yasunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"4267_CR1","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1200\/JCO.2017.72.7602","volume":"35","author":"C Grommes","year":"2017","unstructured":"Grommes C, DeAngelis LM. Primary CNS lymphoma. J Clin Oncol. 2017;35:2410\u20138. https:\/\/doi.org\/10.1200\/JCO.2017.72.7602.","journal-title":"J Clin Oncol"},{"key":"4267_CR2","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1182\/blood.2020008377","volume":"140","author":"LR Schaff","year":"2022","unstructured":"Schaff LR, Grommes C. Primary central nervous system lymphoma. Blood. 2022;140:971\u20139. https:\/\/doi.org\/10.1182\/blood.2020008377.","journal-title":"Blood"},{"key":"4267_CR3","doi-asserted-by":"publisher","first-page":"4570","DOI":"10.1200\/JCO.2006.06.6910","volume":"24","author":"IT Gavrilovic","year":"2006","unstructured":"Gavrilovic IT, Hormigo A, Yahalom J, DeAngelis LM, Abrey LE. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol. 2006;24:4570\u20134. https:\/\/doi.org\/10.1200\/JCO.2006.06.6910.","journal-title":"J Clin Oncol"},{"key":"4267_CR4","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/S1470-2045(10)70229-1","volume":"11","author":"E Thiel","year":"2010","unstructured":"Thiel E, Korfel A, Martus P, Kanz L, Griesinger F, Rauch M, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol. 2010;11:1036\u201347. https:\/\/doi.org\/10.1016\/S1470-2045(10)70229-1.","journal-title":"Lancet Oncol"},{"key":"4267_CR5","doi-asserted-by":"publisher","first-page":"175628641879356","DOI":"10.1177\/1756286418793562","volume":"11","author":"S Low","year":"2018","unstructured":"Low S, Han CH, Batchelor TT. Primary central nervous system lymphoma. Ther Adv Neurol Disord. 2018;11:1756286418793562. https:\/\/doi.org\/10.1177\/1756286418793562.","journal-title":"Ther Adv Neurol Disord"},{"key":"4267_CR6","doi-asserted-by":"publisher","first-page":"3692","DOI":"10.1200\/JCO.22.00491","volume":"40","author":"C Houillier","year":"2022","unstructured":"Houillier C, Dureau S, Taillandier L, Houot R, Chinot O, Molu\u00e7on-Chabrot C, et al. Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients age 60 years and younger: long-term results of the randomized phase II PRECIS study. J Clin Oncol. 2022;40:3692\u20138. https:\/\/doi.org\/10.1200\/JCO.22.00491.","journal-title":"J Clin Oncol"},{"key":"4267_CR7","doi-asserted-by":"publisher","first-page":"799721","DOI":"10.3389\/fonc.2021.799721","volume":"11","author":"J Liu","year":"2021","unstructured":"Liu J, Guo J, Sun X, Liu Y, Gao C. Efficacy and safety of autologous stem-cell transplantation as part of first-line treatment for newly diagnosed primary central nervous system lymphoma: a systematic review and meta-analysis. Front Oncol. 2021;11:799721. https:\/\/doi.org\/10.3389\/fonc.2021.799721.","journal-title":"Front Oncol"},{"key":"4267_CR8","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1182\/blood-2015-10-636340","volume":"127","author":"AJ Ferreri","year":"2016","unstructured":"Ferreri AJ, Illerhaus G. The role of autologous stem cell transplantation in primary central nervous system lymphoma. Blood. 2016;127:1642\u20139. https:\/\/doi.org\/10.1182\/blood-2015-10-636340.","journal-title":"Blood"},{"key":"4267_CR9","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1016\/s0959-8049(00)00171-4","volume":"36","author":"A Hollender","year":"2000","unstructured":"Hollender A, Kvaloy S, Lote K, Nome O, Holte H. Prognostic factors in 140 adult patients with non-Hodgkin\u2019s lymphoma with systemic central nervous system (CNS) involvement. A single centre analysis. Eur J Cancer. 2000;36:1762\u20138. https:\/\/doi.org\/10.1016\/s0959-8049(00)00171-4.","journal-title":"Eur J Cancer"},{"key":"4267_CR10","doi-asserted-by":"publisher","first-page":"882","DOI":"10.3324\/haematol.2022.281640","volume":"108","author":"J Khwaja","year":"2023","unstructured":"Khwaja J, Kirkwood AA, Isbell LK, Steffanoni S, Goradia H, Pospiech L, et al. International multicenter retrospective analysis of thiotepa-based autologous stem cell transplantation for secondary central nervous system lymphoma. Haematologica. 2023;108:882\u20138. https:\/\/doi.org\/10.3324\/haematol.2022.281640.","journal-title":"Haematologica"},{"key":"4267_CR11","doi-asserted-by":"publisher","first-page":"e110","DOI":"10.1016\/S2352-3026(20)30366-5","volume":"8","author":"AJM Ferreri","year":"2021","unstructured":"Ferreri AJM, Doorduijn JK, Re A, Cabras MG, Smith J, Ilariucci F, et al. MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial. Lancet Haematol. 2021;8:e110\u201321. https:\/\/doi.org\/10.1016\/S2352-3026(20)30366-5.","journal-title":"Lancet Haematol"},{"key":"4267_CR12","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40478-018-0522-4","volume":"6","author":"N Shinojima","year":"2018","unstructured":"Shinojima N, Fujimoto K, Makino K, Todaka K, Yamada K, Mikami Y, et al. Clinical significance of polyglutamylation in primary central nervous system lymphoma. Acta Neuropathol Commun. 2018;6:15. https:\/\/doi.org\/10.1186\/s40478-018-0522-4.","journal-title":"Acta Neuropathol Commun"},{"key":"4267_CR13","doi-asserted-by":"publisher","first-page":"4702","DOI":"10.1111\/cas.15133","volume":"112","author":"Y Yamagishi","year":"2021","unstructured":"Yamagishi Y, et al. Liquid biopsy of cerebrospinal fluid for MYD88 L265P mutation is useful for diagnosis of central nervous system lymphoma. Cancer Sci. 2021;112:4702\u201310. https:\/\/doi.org\/10.1111\/cas.15133.","journal-title":"Cancer Sci"},{"key":"4267_CR14","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1200\/JCO.2005.13.524","volume":"23","author":"LE Abrey","year":"2005","unstructured":"Abrey LE, Batchelor TT, Ferreri AJM, Gospodarowicz M, Pulczynski EJ, Zucca E, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005;23:5034\u201343. https:\/\/doi.org\/10.1200\/JCO.2005.13.524.","journal-title":"J Clin Oncol"},{"key":"4267_CR15","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059\u201368. https:\/\/doi.org\/10.1200\/JCO.2013.54.8800.","journal-title":"J Clin Oncol"},{"key":"4267_CR16","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579\u201386. https:\/\/doi.org\/10.1200\/JCO.2006.09.2403.","journal-title":"J Clin Oncol"},{"key":"4267_CR17","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138. https:\/\/doi.org\/10.1038\/bmt.2012.244.","journal-title":"Bone Marrow Transplant"},{"key":"4267_CR18","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.bbmt.2019.01.020","volume":"25","author":"E Kondo","year":"2019","unstructured":"Kondo E, Ikeda T, Izutsu K, Chihara D, Shimizu-Koresawa R, Fujii N, et al. High-dose chemotherapy with autologous stem cell transplantation in primary central nervous system lymphoma: data from the Japan Society for Hematopoietic Cell Transplantation Registry. Biol Blood Marrow Transplant. 2019;25:899\u2013905. https:\/\/doi.org\/10.1016\/j.bbmt.2019.01.020.","journal-title":"Biol Blood Marrow Transplant"},{"key":"4267_CR19","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1182\/blood-2014-10-604561","volume":"125","author":"A Omuro","year":"2015","unstructured":"Omuro A, Correa DD, DeAngelis LM, Moskowitz CH, Matasar MJ, Kaley TJ, et al. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood. 2015;125:1403\u201310. https:\/\/doi.org\/10.1182\/blood-2014-10-604561.","journal-title":"Blood"},{"key":"4267_CR20","doi-asserted-by":"publisher","first-page":"100012","DOI":"10.1016\/j.esmoop.2020.100012","volume":"6","author":"T Magnes","year":"2021","unstructured":"Magnes T, Wagner S, Thorner AR, Neureiter D, Klieser E, Rinnerthaler G, et al. Clonal evolution in diffuse large B-cell lymphoma with central nervous system recurrence. ESMO Open. 2021;6:100012. https:\/\/doi.org\/10.1016\/j.esmoop.2020.100012.","journal-title":"ESMO Open"},{"key":"4267_CR21","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41421-023-00559-7","volume":"9","author":"N Liu","year":"2023","unstructured":"Liu N, Jiang C, Yao X, Fang M, Qiao X, Zhu L, et al. Single-cell landscape of primary central nervous system diffuse large B-cell lymphoma. Cell Discov. 2023;9:55. https:\/\/doi.org\/10.1038\/s41421-023-00559-7.","journal-title":"Cell Discov"},{"key":"4267_CR22","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s12185-021-03263-y","volume":"115","author":"M Nishikori","year":"2022","unstructured":"Nishikori M, Masaki Y, Fujii N, Ikeda T, Takahara-Matsubara M, Sugimoto S, et al. An expanded-access clinical study of thiotepa (DSP-1958) high-dose chemotherapy before autologous hematopoietic stem cell transplantation in patients with malignant lymphoma. Int J Hematol. 2022;115:391\u20138. https:\/\/doi.org\/10.1007\/s12185-021-03263-y.","journal-title":"Int J Hematol"},{"key":"4267_CR23","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1093\/neuonc\/noaa145","volume":"23","author":"Y Narita","year":"2021","unstructured":"Narita Y, Nagane M, Mishima K, Terui Y, Arakawa Y, Yonezawa H, et al. Phase I\/II study of tirabrutinib, a second-generation Bruton\u2019s tyrosine kinase inhibitor, in relapsed\/refractory primary central nervous system lymphoma. Neuro Oncol. 2021;23:122\u201333. https:\/\/doi.org\/10.1093\/neuonc\/noaa145.","journal-title":"Neuro Oncol"},{"key":"4267_CR24","doi-asserted-by":"publisher","first-page":"vdae037","DOI":"10.1093\/noajnl\/vdae037","volume":"6","author":"H Yonezawa","year":"2024","unstructured":"Yonezawa H, Narita Y, Nagane M, Mishima K, Terui Y, Arakawa Y, et al. Three-year follow-up analysis of phase 1\/2 study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma. Neuro-oncol Adv. 2024;6:vdae037. https:\/\/doi.org\/10.1093\/noajnl\/vdae037.","journal-title":"Neuro-oncol Adv"},{"key":"4267_CR25","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1002\/ajh.27316","volume":"99","author":"S Choquet","year":"2024","unstructured":"Choquet S, Soussain C, Azar N, Morel V, Metz C, Ursu R, et al. CAR T-cell therapy induces a high rate of prolonged remission in relapsed primary CNS lymphoma: real-life results of the LOC network. Am J Hematol. 2024;99:1240\u20139. https:\/\/doi.org\/10.1002\/ajh.27316.","journal-title":"Am J Hematol"},{"key":"4267_CR26","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.1182\/blood-2017-01-764209","volume":"129","author":"L Nayak","year":"2017","unstructured":"Nayak L, Iwamoto FM, LaCasce A, Mukundan S, Roemer MGM, Chapuy B, et al. PD-1 blockade with nivolumab in relapsed\/refractory primary central nervous system and testicular lymphoma. Blood. 2017;129:3071\u20133. https:\/\/doi.org\/10.1182\/blood-2017-01-764209.","journal-title":"Blood"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04267-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-026-04267-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04267-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T09:59:23Z","timestamp":1791194363000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-026-04267-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["4267"],"URL":"https:\/\/doi.org\/10.1007\/s12185-026-04267-2","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"assertion":[{"value":"8 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"HT received honoraria from AbbVie, AstraZeneca, Bristol Myers Squibb, Chugai Pharmaceutical, Eisai, Genmab, Gilead Sciences, Janssen, Kyowa Kirin, Meiji Seika, Nippon Shinyaku, Novartis, Ono, SymBio, and Takeda, and patents and royalties from Mesoblasts. SU received honoraria from Swedish Orphan Biovitrum Japan,\u00a0Asahi Kasei Pharma Corporation, Alexion, Novartis Pharmaceuticals, Chugai Pharmaceutical Co.,\u00a0and Argenx\u00a0Japan K.K. KN is an editor of the\n                      International Journal of Hematology\n                      and has received honoraria from Bristol Myers Squibb, Chugai Pharmaceutical, Eisai, Meiji Seika Pharma, AbbVie Inc., Minophagen, Dai-ichi Sankyo, and Kyowa Kirin, along with research funding from Kyowa Kirin and Chugai Pharmaceutical. MY received research funding from Eisai. The remaining authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of Kumamoto University Hospital (No. 2226, Clinical Case Report No. 9) and adhered to the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}